Trials In Focus: How COVID-19 Studies Set New Standards For Collaboration, Diversity
JAMA reports on the COVID-19 Prevention Network’s efforts. Also, Inhibikase said the US FDA lifted a hold on its drug for Parkinson’s disease, while Astellas Pharma said the agency lifted a clinical hold on its gene therapy for Pompe disease. And Trefoil, Theriva Biologics and Nektar initiated new trials.
You may also be interested in...
Inhibikase Back In Game As FDA Lifts Hold On Multiple System Atrophy Drug
The US FDA lifted a clinical hold that it had placed in November after reviewing the company’s INDs to start Phase IIa studies in MSA and Parkinson’s, which was the subject of a hold lifted in January.
Nektar Restructuring Ends Bempeg Ambitions, Cuts Staff By 70%
Following termination of its immuno-oncology partnership with Bristol, Nektar is paring operations, closing its India site and focusing on mid-stage NKTR-358, partnered with Lilly, and NKTR-255.
How To Improve Diversity And Inclusion: Five Companies Share Best Practices
Company strategies at improving diversity, equity and inclusion both within their organizations and in the clinical trials they conduct have differed, but building trust is a common theme.